COOPERVISION, INC.

CooperVision Incorporated is a medical device manufacturer focused on the design, development, and distribution of contact lenses and related vision care products. While its primary NAICS code of 621999 suggests other miscellaneous health services, the company’s core function aligns with the production of Class II medical devices under FDA regulatory frameworks, including daily, monthly, and specialty contact lenses for myopia, astigmatism, and presbyopia. Its technical expertise encompasses polymer science, hydrogel and silicone hydrogel materials, precision molding, and sterile manufacturing processes compliant with ISO 13485 and 21 CFR Part 820. The company’s key differentiators lie in its proprietary lens designs, corneal oxygen permeability optimization, and high-volume aseptic production systems tailored for clinical and consumer healthcare markets. No award history is available to infer specific agency engagements or contract performance data. Consequently, there is no verifiable pattern of work performed for federal, state, or local government entities. The absence of recent awards or agency-specific contract data precludes identification of government program alignment or procurement relationships. The company operates within the medical device manufacturing sector, with its primary activity centered on Class II ophthalmic devices under FDA oversight. Its market positioning is commercial, serving optometrists, ophthalmologists, and retail vision care providers rather than government health systems. CooperVision Incorporated is a large, multi-national corporation structured as a 2L entity with its primary operational base in Victor, New York. It holds no active government certifications such as 8(a), HUBZone, or small business status. Its government market presence cannot be confirmed based on available data, and all known operations appear to be directed toward commercial and international healthcare channels rather than public sector procurement.